Find out about participants

The following countries and agencies took part in the Joint Action for Market Surveillance of Medical Devices (JAMS), contributing in a variety of ways to the outcomes of this work.

There were two types of partners involved in the Joint Action: beneficiaries and collaborating stakeholders.

  • Beneficiaries: these are organisations that received EU co–funding following the successful application and the signature of the grant agreement.
  • Collaborating stakeholders: Organisations that did not have a contractual relationship with Chafea and not receive any EU funding. They contributed to increase the technical and scientific content of the joint action, as well as its relevance for different users in the European Union.
Country Agency Partnership role
Austria Austrian Agency for Health and Food Safety
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
  • Beneficiary partner in Work Package 5: Clinical Process and Resource Development
Belgium Federal Agency for Medicines and Health Products (FAMHP)
  • Collaborative stakeholder partner in Work Package 4: Joint Manufacturer Inspections
Croatia Agencija za lijekove i medicinske proizvode RH (HALMED)
  • Collaborative stakeholder partner in Work Package 5: Clinical Process and Resource Development
Cyprus CYMDA
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
  • Collaborative stakeholder partner in Work Package 5: Clinical Process and Resource Development
Czech Republic MZ CR
  • Collaborative stakeholder partner in Work Package 4: Joint Manufacturer Inspections
Denmark Danish Medicines Agency (DKMA)
  • Collaborative stakeholder partner in Work Package 5: Clinical Process and Resource Development
Estonia Health Board, Medical Devices Department (Terviseamet)
  • Collaborative stakeholder partner in Work Package 4: Joint Manufacturer Inspections
  • Collaborative stakeholder partner in Work Package 5: Clinical Process and Resource Development
France Agence nationale de sécurité du médicament et des produits de santé (ANSM)
  • Joint Action leader
  • Co-Lead with INFARMED (Portugal) for Work Package 4: Joint Manufacturer Inspections
  • Lead for Work Packages 1-3: Coordination; Dissemination; Evaluation
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
  • Beneficiary partner in Work Package 5: Clinical Process and Resource Development
Ireland Health Products Regulatory Authority
  • Lead for Work Package 5: Clinical process and resource development
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
  • Beneficiary partner in Work Package 5: Clinical Process and Resource Development
Italy Ministero Della Salute (SANITA)
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
  • Beneficiary partner in Work Package 5: Clinical Process and Resource Development
Latvia State Agency of Medicines
  • Collaborative stakeholder partner in Work Package 4: Joint Manufacturer Inspections
Portugal National Authority of Medicines and Health Products IP (INFARMED)
  • Co-Lead with ANSM (France) for Work Package 4: Joint Manufacturer Inspections
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
  • Beneficiary partner in Work Package 5: Clinical Process and Resource Development
The Netherlands Dutch Health care Inspectorate (IGZ)
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
  • Beneficiary partner in Work Package 5: Clinical Process and Resource Development
Norway  Norwegian Directorate of Health (Hesedir)
  • Collaborative stakeholder partner in Work Package 4: Joint Manufacturer Inspections
Spain Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
Sweden Medical Products Agency (MPA)
  • Beneficiary partner in Work Package 4: Joint Manufacturer Inspections
UK Medicines and Healthcare products Regulatory Agency
  • Collaborative stakeholder in Work Package 4: Joint Manufacturer Inspections
  • Collaborative stakeholder in Work Package 5: Clinical Process and Resource Development